These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29739808)

  • 21. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
    Deng S; Yang Q; Shu X; Lang J; Lu S
    Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
    [No Abstract]   [Full Text] [Related]  

  • 23. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
    Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
    Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmune complications of immunotherapy: pathophysiology and management.
    Chan KK; Bass AR
    BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors].
    Inaba H; Ariyasu H; Kurimoto C; Iwakura H; Akamizu T
    Gan To Kagaku Ryoho; 2018 Jul; 45(7):1031-1035. PubMed ID: 30042266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
    Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report.
    Lopes AR; Russo A; Li AY; McCusker MG; Kroopnick JM; Scilla K; Mehra R; Rolfo C
    Transl Lung Cancer Res; 2020 Oct; 9(5):2149-2156. PubMed ID: 33209634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models.
    Kim W; Cho YA; Kim DC; Jo AR; Min KH; Lee KE
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.
    Lecis D; Sangaletti S; Colombo MP; Chiodoni C
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31060225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
    Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.
    Brancatella A; Lupi I; Montanelli L; Ricci D; Viola N; Sgrò D; Antonangeli L; Sardella C; Brogioni S; Piaggi P; Molinaro E; Bianchi F; Aragona M; Antonuzzo A; Sbrana A; Lucchesi M; Chella A; Falcone A; Del Prato S; Elisei R; Marcocci C; Caturegli P; Santini F; Latrofa F
    J Endocr Soc; 2021 Sep; 5(9):bvab093. PubMed ID: 34337277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review.
    Liu C; Seeram NP; Ma H
    Cancer Cell Int; 2021 Apr; 21(1):239. PubMed ID: 33906641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.